Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Status:
Completed
Trial end date:
2013-10-14
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC)
evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering
therapy.